Client
EpiCept Corporation, New Jersey, United States
Specialty pharmaceutical company with a proprietary technology for the topical delivery of prescription medications for the treatment of pain.
Mandate
Evaluate strategic alternatives
Our Role
Retained advisor to the Board of Directors and management
- Attended Board meetings in person or via conference call.
- Assisted management in contacting and evaluating potential underwriters to support an initial public offering.
- Organized investment banking ‘bake-off’ with interested underwriters.
- Guided management in selecting a lead underwriter and two co-managers.
- Assisted management in negotiating syndicate economics and underwriting agreement.
- Facilitated contact to the Board of Maxim Pharmaceuticals, Inc., when initial public offering was pulled due to market conditions.
- Consulted management and the Board on a reverse merger of the Company into Maxim Pharmaceuticals, Inc.
N.B. Consulting services performed prior to the formation of CATALYSIS CAPITAL PARTNERS LTD. and authorisation and regulation by FCA UK
